Use of Impella device in cardiogenic shock and its clinical outcomes: A systematic review and meta-analysis.

Int J Cardiol Heart Vasc · 2022 · PMC8961185 · PMID 35360892

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

While a nonsignificant trend towards a mortality benefit with Impella was observed in the subgroup of studies with a higher percentage of adoption of higher MCS (RR = 0.94; 95% CI 0.77–1.15; p = 0.529), short-term mortality was significantly lower with IABP in the subgroup of studies with lower adoption of a high MCS (RR = 1.26; 95% CI 1.08–1.48; p = 0.005) (Supplementary Fig. 4).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.